Cited 0 times in

102 57

뇌졸중 최신지견 2011: 새로운 항혈전제

Other Titles
 Stroke Update 2011: New Antithrombotics. 
Authors
 서권덕 ; 이경열 
Citation
 Korean Journal of Stroke, Vol.14(2) : 62~66, 2012 
Journal Title
 Korean Journal of Stroke 
ISSN
 1229-4101 
Issue Date
2012
Abstract
Several new antithrombotic drugs have been developed and approved to use in clinical practice recently. Dabigatran, a direct thrombin inhibitor, and rivaroxaban, a factor Xa inhibitor, have been approved in many countries including Korea to prevent stroke in patient with atrial fibrillation. Apixaban, another factor Xa inhibitor, showed good results in clinical trial and is waiting for approval for clinical use. New antiplatelet agent, terutroban, selective thromboxane A2 receptor inhibitor, failed to prove the efficacy over the aspirin in secondary stroke prevention. Vorapaxar, a new antiplatelet agent that inhibits thrombin through PAR-1 antagonism, showed a high incidence of intracranial hemorrhage in patient with a history of stroke.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/91346
DOI
10.5853/kjs.2012.14.2.62
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Neurology
Yonsei Authors
사서에게 알리기
  feedback
Files in This Item:
T201203824.pdfDownload
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse